Nuvalent | Investor Presentation Deck

Slide schematic 9/9

list 4/4 paragraph 2/2 source-note 1/1 title 2/2

Components 9

bullet bullet bullet bullet paragraph paragraph source-note action-title headline

Tools 1

list/bullet: Clinical activity observed in heavily pretreated patients with ROS1+ NSCLC: Who likely exhausted all available therapies (ORR: 50%); With ROS1 resistance mutations (ORR: 78%); With history of CNS metastasis

Metrics 0

∅

No metrics

No metric insight is anchored to this slide.

Frameworks 0

∅

No frameworks

No framework match is anchored to this slide.

Find anything

The slide uses a comparative structure to contrast the 2L+ (salvage) and 1L (frontline) market opportunities.